Warfarin

Fasting and warfarin

Warfarin pharmacogenomics.

Warfarin, an anticoagulant, is used to prevent and treat thromboembolic disease. One of the drawbacks of this agent, also known as Coumadin (Bristol-Myers Squibb), is that it is difficult to administer at the correct dose as a result of its narrow therapeutic index, its tendency to cause bleeding, and the individual variability in patient response. Achieving safe and effective doses of warfarin...

Warfarin Versus Warfarin and Aspirin in Atrial Fibrillation

Background Anticoagulation with warfarin is an important therapy for preventing strokes in patients with atrial fibrillation (AF). Physicians often combine warfarin with aspirin despite evidence for increased bleeding. We investigated the hemorrhagic outcomes related to the differential management of AF with warfarin alone versus combination therapy. Methods and Results This retrospective cohor...

Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile

Warfarin-related nephropathy (WRN) is a renal complication of warfarin treatment associated with over-anticoagulation. We describe a case of a 73-year-old man affected by chronic kidney disease, essential hypertension and atrial fibrillation treated with warfarin. The patient presented a rapid course of kidney failure after many episodes of over-anticoagulation, and renal biopsy demonstrated WR...

Warfarin discontinuation after starting warfarin for atrial fibrillation.

BACKGROUND Although warfarin is widely recommended to prevent atrial fibrillation-related thromboembolism, many eligible patients do not take warfarin. The objective of this study was to describe factors associated with warfarin discontinuation in patients newly starting warfarin for atrial fibrillation. METHODS AND RESULTS We identified 4188 subjects newly starting warfarin in the Anticoagul...